The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Sponsor
University Hospital Dubrava
Study ID
NCT06969586
Status
Enrolling By Invitation

Conditions

  • Cataract
  • Fuchs Endothelial Corneal Dystrophy
  • Glaucoma

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil 0.02% Ophthalmic Solution — DRUG
    Topical Netarsudil 0.02% 1x daily for 30 days postoperatively
  • artificial tear substitute — DRUG
    Topical artificial tear substitute 1x daily for 30 days postoperatively.

Study Details

The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug) Participants will: Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.

Key Dates

Start date
Apr 1, 2025
Status verified
May 2025
Primary completion
Apr 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: ROCK inhibitor group
    Patients with Fuchs Endothelial Corneal Dystrophy and glaucoma scheduled for cataract surgery. ROCK inhibitor group will receive topical ROCK inhibitor for 30 days postoperatively.
  • Arm: Placebo group
    Patients with Fuchs Endothelial Corneal Dystrophy and glaucoma scheduled for cataract surgery. ROCK inhibitor group will receive topical placebo for 30 days postoperatively.

Primary Outcome Measure

Endothelial cell density (ECD) [ Time Frame: 37 days ]

Related Studies